12:27
BioNTech
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals
German biotech firm BioNTech (22UAy.DE), has agreed to acquire domestic peer CureVac, for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.
